5 November 2019 in Journal of Medicinal Chemistry
The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors. While tumor responses to tyrosine kinase inhibitors (TKIs) are accompanied by marked tumor shrinkage, the response is usually not durable. Most patients relapse within two years of therapy often due to acquisition of an additional mutation in EGFR kinase domain that confers resistance to TKIs. Crucially, oncogenic EGFR harboring both resistance mutations, T790M and C797S, can no longer be inhibited by currently approved EGFR TKIs. Here, we describe the discovery of BI-4020, which is a non-covalent, wild-type EGFR sparing, macrocyclic TKI. BI-4020 potently inhibits the above described EGFR variants and induces tumor regressions in a cross-resistant EGFRdel19 T790M C797S xenograft model. Key was the identification of a highly selective but moderately potent benzimidazole followed by complete rigidification of the molecule through macrocyclization.
5 August 2019 in Journal of the American Chemical Society
6 October 2014 in Synthesis
The recent development and progress of early-transition-metal-catalyzed C–H alkylation adjacent to nitrogen of unprotected amines with alkenes are summarized. Group 4 and 5 metal complexes are very effective for hydroaminoalkylation catalysis, an emerging atom-economic C(sp3)–C(sp3) bond formation strategy. 1 Introduction 2 Group 4 Hydroaminoalkylation Catalysis 2.1 Intramolecular Hydroaminoalkylation 2.2 Intermolecular Hydroaminoalkylation 3 Group 5 Hydroaminoalkylation Catalysis 4 Conclusions and Outlook
10 August 2015 in Journal of the American Chemical Society
This communication demonstrates the first catalytic aminoboration of C–C π bonds by B–N σ bonds and its application to the synthesis of 3-borylated indoles. The regiochemistry and broad functional group compatibility of this addition reaction enable substitution patterns that are incompatible with major competing technologies. This aminoboration reaction effects the formation of C–B and C–N bonds in a single step from aminoboronic esters, which are simple starting materials available on the gram scale. This reaction generates synthetically valuable N-heterocyclic organoboron compounds as potential building blocks for drug discovery. The working mechanistic hypothesis involves a bifunctional Lewis acid/base catalysis strategy involving the combination of a carbophilic gold cation and a trifluoroacetate anion that activate the C–C π bond and the B–N σ bond simultaneously.
20 July 2014 in Journal of the American Chemical Society
20 April 2017 in Journal of the American Chemical Society